CO2023016367A2 - Moduladores de trex1 - Google Patents

Moduladores de trex1

Info

Publication number
CO2023016367A2
CO2023016367A2 CONC2023/0016367A CO2023016367A CO2023016367A2 CO 2023016367 A2 CO2023016367 A2 CO 2023016367A2 CO 2023016367 A CO2023016367 A CO 2023016367A CO 2023016367 A2 CO2023016367 A2 CO 2023016367A2
Authority
CO
Colombia
Prior art keywords
trex1
modulators
compositions
treating
compounds
Prior art date
Application number
CONC2023/0016367A
Other languages
English (en)
Inventor
Avinash Khanna
Julian R Levell
Jonathan E Wilson
Aaron Coffin
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of CO2023016367A2 publication Critical patent/CO2023016367A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Amplifiers (AREA)

Abstract

Se proveen compuestos de fórmula (I) y sales farmacéuticamente aceptables y composiciones de los mismos, que son útiles para tratar una variedad de afecciones asociadas a TREX1.
CONC2023/0016367A 2021-05-05 2023-11-29 Moduladores de trex1 CO2023016367A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163184460P 2021-05-05 2021-05-05
PCT/US2022/027571 WO2022235725A1 (en) 2021-05-05 2022-05-04 Modulators of trex1

Publications (1)

Publication Number Publication Date
CO2023016367A2 true CO2023016367A2 (es) 2024-02-05

Family

ID=82016366

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0016367A CO2023016367A2 (es) 2021-05-05 2023-11-29 Moduladores de trex1

Country Status (13)

Country Link
EP (1) EP4333985A1 (es)
JP (1) JP2024516289A (es)
KR (1) KR20240035385A (es)
CN (1) CN117561251A (es)
AU (1) AU2022269596A1 (es)
BR (1) BR112023022917A2 (es)
CA (1) CA3217421A1 (es)
CL (1) CL2023003253A1 (es)
CO (1) CO2023016367A2 (es)
CR (1) CR20230569A (es)
DO (1) DOP2023000241A (es)
IL (1) IL308220A (es)
WO (1) WO2022235725A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9328075B2 (en) * 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
WO2014023691A1 (en) * 2012-08-06 2014-02-13 Savira Pharmaceuticals Gmbh Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
PE20212070A1 (es) * 2018-12-06 2021-10-26 Constellation Pharmaceuticals Inc Moduladores de trex1
CA3147419A1 (en) * 2019-07-23 2021-01-28 Constellation Pharmaceuticals, Inc. Modulators of trex1

Also Published As

Publication number Publication date
CL2023003253A1 (es) 2024-05-03
DOP2023000241A (es) 2024-02-29
BR112023022917A2 (pt) 2024-01-23
JP2024516289A (ja) 2024-04-12
EP4333985A1 (en) 2024-03-13
CA3217421A1 (en) 2022-11-10
WO2022235725A1 (en) 2022-11-10
CN117561251A (zh) 2024-02-13
IL308220A (en) 2024-01-01
CR20230569A (es) 2024-01-22
KR20240035385A (ko) 2024-03-15
AU2022269596A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
CL2021001461A1 (es) Moduladores de trex1
CO2018008759A2 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
CO6300939A2 (es) Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada
ECSP089019A (es) Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa
DOP2019000140A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
CO2020013840A2 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados
CL2023000594A1 (es) Compuestos heterocíclicos
UY39150A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CO2023015732A2 (es) Moduladores de trex1
CL2022001951A1 (es) Compuestos heterocíclicos novedosos útiles como inhibidores selectivos de aurora a
CO2023014721A2 (es) Compuestos heterocíclicos
CO2023016204A2 (es) Inhibidores de nlrp3
AR128500A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
CU20220025A7 (es) Inihibidores del factor d del complemento para administración oral
CO2022004305A2 (es) Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3
DOP2011000053A (es) Agentes antifungicos
CO2021004873A2 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
CO2023016367A2 (es) Moduladores de trex1
CO2021017202A2 (es) Compuestos tricíclicos
UY38498A (es) Inhibidores de o-glucoproteina-2- acetamido-2-desoxi-3-d-glucopiranosidasa de morfolinilo , piperazinilo , oxazepanilo y diazepanilo
AR128426A1 (es) Compuestos heterocíclicos y métodos de uso